Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Seneca Therapeutics Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are distributed among 2 distinct examiners, meaning each examiner is currently reviewing 1 application or matter.
The prosecution spans 2 distinct art units. This distribution indicates that while the technology remains within Biotechnology & Pharmaceuticals, the specific claims are categorized into 2 different specialized units at the USPTO. Valarie E Bertoglio is identified as the busiest examiner for this portfolio, with 1 pending office action currently under her review.
With 2 pending office actions and 2 distinct examiners, the company must manage 2 separate examiner relationships. The 2 distinct art units suggest that the legal strategy may need to be tailored to the specific nuances of each unit, even though the busiest examiner, Valarie E Bertoglio, only handles 1 of the 2 pending actions. This spread of 2 examiners for 2 actions ensures that each examiner handles 1 pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.2% |
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272986 | ARMED SENECA VALLEY VIRUS ONCOLYTIC THERAPY COMPOSITIONS AND METHODS THEREOF | BERTOGLIO, VALARIE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272986 | ARMED SENECA VALLEY VIRUS ONCOLYTIC THERAPY COMPOSITIONS AND METHODS THEREOF | BERTOGLIO, VALARIE E | — |
| 18271619 | SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18272986 | ARMED SENECA VALLEY VIRUS ONCOLYTIC THERAPY COMPOSITIONS AND METHODS THEREOF | BERTOGLIO, VALARIE E | 1632 | §102§103§112 | Final Rejection | — | Pending | Jul 18, 2023 |
| 18271619 | SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR | BEANE, RANDALL L | 1654 | §103DP | Final Rejection | — | Pending | Jul 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial